STOCK TITAN

BeiGene Ltd - BGNE STOCK NEWS

Welcome to our dedicated news page for BeiGene (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BeiGene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BeiGene's position in the market.

Rhea-AI Summary
BeiGene's Phase 3 RATIONALE 315 study shows positive results for tislelizumab in patients with resectable NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
clinical trial
-
Rhea-AI Summary
BeiGene announces positive results from Phase 3 RATIONALE 305 trial of tislelizumab plus chemotherapy in gastric cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
Rhea-AI Summary
BeiGene presents promising data on tislelizumab at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
none
Rhea-AI Summary
CHMP recommends approval for BRUKINSA plus obinutuzumab as a treatment for adult patients who have received at least two prior lines of therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary
BeiGene's TEVIMBRA receives European Commission approval for the treatment of advanced or metastatic ESCC, while the FDA accepts the Biologics License Application for first-line treatment of ESCC. Positive results from clinical trials show survival benefit and potential for addressing unmet clinical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
Rhea-AI Summary
BeiGene regains worldwide rights to develop, manufacture, and commercialize TEVIMBRA (tislelizumab) from Novartis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
Rhea-AI Summary
BeiGene to participate in Morgan Stanley conference on September 11th, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
conferences
-
Rhea-AI Summary
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) reported a total product revenue of $554 million in Q2 2023, an 82% increase from the prior-year period. Global sales of BRUKINSA totaled $308 million, marking a 139% increase from the previous year. The company also highlighted positive regulatory progress and development programs, including approvals and regulatory submissions for BRUKINSA and Tislelizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
earnings
-
Rhea-AI Summary
BeiGene receives positive opinion from CHMP for tislelizumab as monotherapy for esophageal squamous cell carcinoma after prior chemotherapy. The Phase 3 study showed a statistically significant and clinically meaningful survival benefit for tislelizumab compared to chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
Rhea-AI Summary
BeiGene's sNDA for BRUKINSA in combination with obinutuzumab for the treatment of relapsed or refractory follicular lymphoma has been accepted for review by the FDA. The target action date is set for the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
clinical trial
BeiGene Ltd

Nasdaq:BGNE

BGNE Rankings

BGNE Stock Data

16.96B
760.97M
19.85%
48.17%
1.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Changping District

About BGNE

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.